There are concerns regarding increased risk of acute coronary syndrome with dabigatran. We aimed to assess whether alternative treatment options such as rivaroxaban or apixaban carry a similar risk as compared to dabigatran.
|Number of pages||11|
|Journal||British Journal of Clinical Pharmacology|
|Early online date||11 Mar 2014|
|Publication status||Published - Oct 2014|
- acute coronary syndrome